Resection margin distance in extrahepatic cholangiocarcinoma: How much is enough?

Authors

null

Amir A. Rahnemai-Azar

University of Wisconsin Hospital, Madison, WI

Amir A. Rahnemai-Azar , Sean Ronnekleiv-Kelly , Daniel Abbott , Cecilia Grace Ethun , George A. Poultsides , Thuy Tran , Ryan Fields , Bradley Aaron Krasnick , Robert C. G. Martin II, Charles Raben Scoggins , Kamran Idrees , Chelsea A Isom , Ioannis Hatzaras , Rivfka Shenoy , Perry Shen , James D. Perkins , Timothy M. Pawlik , Shishir K. Maithel , Sharon M. Weber

Organizations

University of Wisconsin Hospital, Madison, WI, University of Wisconsin School of Medicine and Public Health, Madison, WI, University of Wisconsin Carbone Cancer Center, Madison, WI, Emory University Winship Cancer Institute, Atlanta, GA, Stanford University School of Medicine, Stanford, CA, Department of Surgery, Stanford University School of Medicine, Stanford, CA, Washington University School of Medicine in St. Louis, St. Louis, MO, Norton Healthcare Pavillion, Louisville, KY, University of Louisville, Louisville, KY, Vanderbilt University Medical Center, Nashville, TN, Division of Surgical Oncology, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, NYU Langone Medical Center, New York, NY, Department of Surgery, New York University School of Medicine, New York, NY, Division of Surgical Oncology, Department of Surgery, Wake Forest University School of Medicine, Winston-Salem, NC, University of Washington, Seattle, WA, Johns Hopkins University School of Medicine, Baltimore, MD, Winship Cancer Institute, Emory University, Atlanta, GA

Research Funding

Other

Background: Surgical resection is required for curative treatment of patients with extra-hepatic cholangiocarcinoma (EH-CCA). The objective of this study was to determine if the distance of surgical margin was associated with outcome. Methods: Patients who underwent curative-intent resection for EH-CCA between 2000 and 2015 at 10 hepatobiliary centers across the U.S. were evaluated using prospectively collected data. Cox proportional hazard model was utilized to evaluate the influence of the extent of the margin on outcome. Results: 538 patients with EH-CCA who underwent curative-intent resection were included: 383 (71%) undergoing R0 resection, 153 (28%) undergoing R1 resection, and 2 with R2 resection. A negative surgical margin (R0) was associated with improved recurrence-free (RFS) and overall survival (OS) (RFS: 10.5% vs. 3.6% (R1) and OS: 25.8% vs. 9.3% (R1). Subsequently, further analysis on 161 patients with complete data on distance of resection margin, all undergoing R0 resection, was performed to assess the impact of extent of margin on outcome. On multi-variable analysis, the resection margin distance, analyzed as a continuous variable, was not associated with either improved RFS (RR 1.00, 95% CI 0.96-1.05; p 0.71) or OS (RR 0.99, 95% CI 0.96-1.01; p 0.49). Increasing age, increased tumor size, and LN metastasis were identified as independent predictors of OS; while RFS were mainly dependent on tumor size and LN metastasis (Table). Conclusions: Achieving R0 resection is acceptable for EH-CCA tumors, and obtaining additional margin does not confer a benefit on overall survival. Increasing age, tumor size, and LN metastasis are independent predictors of RFS and OS, but increased margin width is not associated with improvement in either. Multivariable analysis of factors affecting OS of patients with extra-hepatic CCA who underwent surgical resection, with significant factors noted in bold.

VariableRRCI
Closest margin distance0.990.96- 1.01
Preoperative biopsy0.680.44- 1.06
Male gender1.400.92- 2.19
Lymphovascular invasion1.320.83- 2.12
Perineural invasion0.790.51- 1.28
Age1.031.01- 1.05
Tumor size1.021.00- 1.03
Lymph node positive1.871.21- 2.89

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 455)

DOI

10.1200/JCO.2019.37.4_suppl.455

Abstract #

455

Poster Bd #

P15

Abstract Disclosures

Similar Abstracts

First Author: Malcolm MacKenzie

First Author: Sameh Hany Emile

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Timing of primary tumor resection after systemic chemotherapy initiation among patients with metastatic colon cancer.

First Author: Munir Buhaya

First Author: Nuri Karadurmus